Oxysterols and Their Cellular Effectors

Vesa M. Olkkonen 1,2,* Olivier Béaslas 1 and Eija Nissilä 1,2

1 Minerva Foundation Institute for Medical Research, Biomedicum 2U, Tukholmankatu 8, FI-00290 Helsinki, Finland; E-Mails: olivier.beaslas@helsinki.fi (O.B.); eija.nissila@helsinki.fi (E.N.)
2 Institute of Biomedicine, Anatomy, Biomedicum 1, Haartmaninkatu 8, FI-00014 University of Helsinki, Finland

* Author to whom correspondence should be addressed; E-Mail: vesa.olkkonen@helsinki.fi; Tel.: +358-9-19125705; Fax: +358-9-19125701.

Received: 29 December 2011; in revised form: 3 February 2012 / Accepted: 7 February 2012 / Published: 15 February 2012

Abstract: Oxysterols are oxidized 27-carbon cholesterol derivatives or by-products of cholesterol biosynthesis, with a spectrum of biologic activities. Several oxysterols have cytotoxic and pro-apoptotic activities, the ability to interfere with the lateral domain organization, and packing of membrane lipids. These properties may account for their suggested roles in the pathology of diseases such as atherosclerosis, age-onset macular degeneration and Alzheimer’s disease. Oxysterols also have the capacity to induce inflammatory responses and play roles in cell differentiation processes. The functions of oxysterols as intermediates in the synthesis of bile acids and steroid hormones, and as readily transportable forms of sterol, are well established. Furthermore, their actions as endogenous regulators of gene expression in lipid metabolism via liver X receptors and the Insig (insulin-induced gene) proteins have been investigated in detail. The cytoplasmic oxysterol-binding protein (OSBP) homologues form a group of oxysterol/cholesterol sensors that has recently attracted a lot of attention. However, their mode of action is, as yet, poorly understood. Retinoic acid receptor-related orphan receptors (ROR) α and γ, and Epstein-Barr virus induced gene 2 (EBI2) have been identified as novel oxysterol receptors, revealing new physiologic oxysterol effector mechanisms in development, metabolism, and immunity, and evoking enhanced interest in these compounds in the field of biomedicine.

Keywords: cell signaling; EBI2; Insig; lipid metabolism; LXR; OSBP; oxysterol; oxysterol-binding protein; oxysterol receptor; ROR
1. Introduction

Oxysterols are 27-carbon oxidized derivatives of cholesterol or by-products of the cholesterol biosynthetic process with multiple biological activities. Several major oxysterols arise as intermediates in the pathways converting cholesterol to bile acids or steroid hormones, and their roles as readily transportable forms of sterol are well established [1–3]. The common oxygen-containing modifications of cholesterol in oxysterols are hydroxyl, keto, hydroperoxy, epoxy, and carboxyl moieties. In general, oxysterols have a drastically shorter biologic half-life than cholesterol—they can therefore be considered a way to route the cholesterol molecule for catabolism. The physiologically most important oxysterols are generated in cells by mitochondrial or endoplasmic reticulum cholesterol hydroxylases belonging to the cytochrome P450 family [4,5]. Of these species, the most abundant in human serum are 27-, 24(S)-, 7α-, and 4β-hydroxycholesterol (OHC). Of these, 24(S)-OHC originates from neurons in the central nervous system, the sterol homeostasis of which depends on the synthesis of this oxysterol catalyzed by the cholesterol hydroxylase CYP46A1 [6], 7α- and 27-OHC are synthesized by the liver by CYP7A1 and CYP27A1 as the first intermediates of classic and acidic bile acid synthetic pathways, respectively [7]; CYP27A1 however is functional also in non-hepatic cells [8]. 4β-OHC is generated by the hepatic drug metabolizing enzyme CYP3A4, which is markedly induced by certain anti-epileptic pharmaceuticals [9]. Oxysterols also arise in vivo or during food processing through non-enzymatic, free radical, lipid peroxide, or divalent cation-induced oxidative processes, often termed cholesterol autoxidation [10]. The most abundant oxysterols generated through autoxidation are modified at the 7-position of the cholesterol B-ring. These include 7-ketocholesterol (7-KC) and 7β-OHC with prominent cytotoxic and pro-apoptotic properties [11]. Structures of the most abundant oxysterols and the routes of their synthesis are depicted in Figure 1 [2], and the nomenclature of these oxysterols is specified in Table 1.

| Abbreviation | Common name | IUPAC name |
|--------------|-------------|------------|
| β-EPOX      | 5β,6β-epoxycholesterol | Cholestan-5β,6β-epoxy-3β-ol |
| α-TRIOL     | 4β-epoxycholesterol | Cholestan-3β,5α,6β-triol |
| 4β-OHC      | 7α-hydroxycholesterol | Cholest-5-en-3β,4β-diol |
| 7α-OHC      | 7α-hydroxycholesterol | Cholest-5-en-3β,7α-diol |
| 7β-OHC      | 7β-hydroxycholesterol | Cholest-5-en-3β,7β-diol |
| 7-KC        | 7-ketocholesterol | Cholest-5-en-3β-ol-7-one |
| 25-OHC      | 25-hydroxycholesterol | Cholest-5-en-3β,25-diol |
| 27-OHC      | 27-hydroxycholesterol | (25R)-cholest-5-en-3β,26-diol |
| 22(R)-OHC   | 22(R)-hydroxycholesterol | (22R)-cholest-5-en-3β,22-diol |
| 20(S)-OHC   | 20(S)-hydroxycholesterol | (20S)-cholest-5-en-3β,20-diol |
| 24(S)-OHC   | 24(S)-hydroxycholesterol | (24S)-cholest-5-en-3β,24-diol |
| 24(S),25-EPOX | 24(S),25-epoxycholesterol | (24S,25)-epoxycholesterol-5-en-3β-ol |
| 7α,25-OHC   | 7α,25-hydroxycholesterol | Cholest-5-en-3β,7α,25-triol |
**Figure 1.** Structure and origin of selected common oxysterols. Most of the oxysterol species displayed are generated by enzymes that belong to the cytochrome P450 family (CYP). CH25H, cholesterol 25-hydroxylase, is a di-iron enzyme. The enzymatically derived species are indicated with green, products of cholesterol autoxidation with red, and a species derived from a shunt of the cholesterol biosynthetic process with blue print (Modified from [2] with kind permission from Springer Science+Business Media B.V.).

Oxysterols are present in mammalian tissues at very low concentrations, as mixtures accompanied by a high excess of cholesterol. However, they are found enriched in pathologic structures such as macrophage foam cells, atherosclerotic lesions, cataracts, and gall stones. The cytotoxic and pro-apoptotic actions of oxysterols are suggested by play a role in the disease processes involved [12–15]. Moreover, oxysterols have been implicated in the pathology of degenerative diseases such age-onset macular degeneration and Alzheimer’s disease [16,17]. The above findings, as well as the potent regulatory activity that several oxysterols have on cellular cholesterol homeostatic machineries (reviewed by Gill et al. [18]), have prompted intensive research of oxysterols in the context of lipid homeostasis and atherosclerosis. However, novel physiologic activities of these compounds have emerged. Oxysterols are believed to act as endogenous regulators of gene expression in lipid metabolism and as signaling molecules with key roles in developmental, differentiation, and inflammation processes. Recently, novel oxysterol receptors responsible for these activities have been identified, opening new perspectives to oxysterol function and evoking novel interest in these compounds in the field of biomedical research. The present review focuses on the newly identified receptors and cellular effector pathways of oxysterols.
2. Oxysterols in Transcriptional Control of Lipid Metabolism

2.1. Oxysterols Act as Ligands of Liver X Receptors

The pioneering work by D. Mangelsdorf’s group revealed that the orphan nuclear receptors liver X receptor (LXR) α (NR1H3) and β (NR1H2) are activated by oxysterol ligands [19]. The physiologically most important endogenous LXR ligands are most likely 24(S),25-EPOX, 24(S)-OHC, 22(R)-OHC, 20(S)-OHC, and 27-OHC [19–21]. LXRα is expressed at highest amounts in liver, but also in adipose tissue, intestine, kidney, and macrophages, while LXRβ is ubiquitously expressed. The LXRs form heterodimers with retinoid X receptor (RXR) and play central roles in sterol absorption in the intestine, the reverse cholesterol transport process, bile acid synthesis, biliary neutral sterol secretion, hepatic lipogenesis, and synthesis of nascent high-density lipoproteins [22]—the LXRs have also been established as suppressors of inflammatory gene expression in macrophage [23,24], and recent studies have established an increasing number of LXR functions in immune regulation (see 3.4.). Studies employing atherosclerosis-prone mouse models have revealed anti-atherogenic function of the LXRs [25,26]. However, LXR stimulation with synthetic agonists such as T0901317 also leads, via a lipogenic activity, to hepatic steatosis and increased serum triglyceride levels, which represents an atherosclerosis risk factor [27]. This caveat can be avoided via the use of intestine-specific LXR activation leading to reduced cholesterol absorption, as demonstrated by genetic and pharmacologic approaches [28,29]. While there is some controversy as to whether oxysterols truly act as endogenous ligands of the LXR [1]: The work by Chen et al. [30] provided evidence that this indeed is the case: Overexpression of an oxysterol catabolic enzyme, cholesterol sulfotransferase, was shown to inactivate LXR signaling in several cultured mammalian cell lines but did not alter receptor response to the nonsterol LXR agonist T0901317. Moreover, triple-knockout mice deficient in the biosynthesis of three oxysterol ligands of LXRs, 24(S), 25-, and 27-OHC, responded to dietary T0901317 by inducing LXR target genes but showed impaired responses to dietary cholesterol, supporting the view that conversion of cholesterol to oxysterols is important for LXR activation in vivo. On the other hand, the recent report by Shafaati et al. [31] showed that overexpression of CYP46A1 in transgenic mice under the β-actin promoter, resulting in significantly elevated 24(S)-OHC levels, failed to induce LXR target genes in either brain or liver. This data argues against a role of 24(S)-OHC, which is in vitro a potent LXR activator, as an important endogenous LXR agonist.

2.2. Oxysterols Regulate SREBP Maturation

The cellular machinery for cholesterol biosynthesis and uptake, as well as for fatty acid biosynthesis, is controlled by transcription factors designated sterol regulatory element binding proteins (SREBPs) [32,33]. The intracellular localization and proteolytic maturation of SREBPs are regulated by a cholesterol-sensor protein called the SREBP cleavage activating protein (SCAP). The SREBPs are synthesized as precursors anchored to ER membranes and form complexes with SCAP. Under low-cholesterol conditions, SREBP-SCAP complexes are transported by a coat protein complex II (COPII)-dependent mechanism to the Golgi apparatus, where SREBPs are proteolytically processed to release a basic helix-loop-helix leucine zipper transcription factor, which enters the nucleus and binds to sterol regulatory elements (SRE) in the promoters of target genes. When sterol builds up in
cells, SCAP senses cholesterol in the ER membranes and interacts with Insig (Insulin-induced gene) proteins, and as a result the SREBP-SCAP complex is retained in the ER. The transport of SREBP to the Golgi complex is sensitive to both cholesterol and several oxysterols, of which 25-OHC is most commonly used in experimental set-ups. While SCAP senses ER cholesterol, it was not found to bind 25-OHC [34,35], raising the question of how the inhibitory effect of oxysterols could be mediated. Intriguingly, the Insig proteins were found to directly bind 25-OHC and to mediate the regulatory effect of this oxysterol on SREBP processing. Binding of the Insig-25-OHC complex to SCAP elicits a conformational change similar to that induced by cholesterol binding to SCAP. This precludes the interaction of SCAP with COPII proteins and thereby the transport and proteolytic activation of SREBP [36,37]. Interestingly, Lange et al. [38] found that the mitochondrial cholesterol 27-hydroxylase (CYP27A1) is required for the rapid inactivation of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCoAR) in response to high levels of cholesterol. This is most likely due to 27-OHC interaction with Insig, resulting in the ubiquitination and degradation of HMGCoAR (see [33]). Vertebrates thus have two sterol sensors that control SREBP activity, enabling cells to down-regulate their sterol biosynthesis upon the build-up of either cholesterol or its oxidized derivatives.

24(S),25-epoxycholesterol [24(S),25-EPOX] is generated as a side product of the cholesterol biosynthetic process by the same enzymes that catalyze the synthesis of cholesterol [39]. 24(S),25-EPOX is a potent feedback regulator of cholesterol biosynthesis, suppressing SREBP-2 processing [40] and the cellular HMGCoAR activity [41]. It is also a highly potent oxysterol activator of the LXRs [20,30,42]. The cellular level of 24(S),25-EPOX can be manipulated either by using inhibitors of the cholesterol biosynthetic pathway enzyme 2,3-oxidosqualene cyclase (OSC), resulting in elevation of cellular 24(S),25-EPOX levels, or by overexpressing this enzyme to reduce the cellular content of the oxysterol. Using these tools the groups of A. Brown and M. Huff [43–47] have significantly added to our understanding of the physiologic role of 24(S),25-EPOX. Beyea et al. [43] demonstrated that partial inhibition of OSC in THP-1 macrophages reduced cholesterol synthesis and increased the expression of several LXR target genes, ABCA1, ABCG1, and APOE. Importantly, OSC inhibition did not stimulate lipoprotein lipase (LPL) or fatty acid synthase (FAS), and the observed induction of the lipogenic transcription factor SREBP-1c was counteracted by a block in its conversion to the active nuclear form, supporting the notion that OSC inhibition might have therapeutic potential [44]. However, this idea is undermined by the finding that 24(S),25-EPOX strongly inhibits cholesterol efflux from macrophage foam cells, possibly due to inhibition of cholesterol ester hydrolase function [48]. The findings of Wong et al. [45,46] suggest that synthesis of 24(S),25-EPOX parallels that of cholesterol and fine-tunes the acute control of cellular cholesterol homeostasis, thus protecting cells against accumulation of newly synthesized cholesterol.

Interestingly, 24(S),25-EPOX is also suggested to have a specific role in CNS sterol homeostasis. Wong et al. [47] demonstrated that this oxysterol is produced by astrocytes and is taken up by neurons in which it impacts gene expression. The authors suggested that 24(S),25-EPOX may act as a signal from astrocytes that reduces the energetically costly cholesterol biosynthesis by neurons, enabling the neurons to direct resources to other processes essential for neurotransmission.
2.3. Oxysterols Modulate the Activity of RORα and γ

The retinoic acid receptor-related orphan receptors (RORs) are nuclear receptors that, as one of their physiologic functions, have been implicated in the transcriptional control of lipid metabolism. RORα (NR1F1) plays an essential role in development of the cerebellum and in regulation of the circadian rhythm [49], while RORγ (NR1F3) is best known for its role in regulation of T cell development [50]. Both RORα and RORγ are expressed in the liver and play roles in the regulation of glucose and lipid metabolism [51]. The group of T. Burris discovered in 2010 that the 7-substituted oxysterols bound to the ligand binding domains (LBDs) of RORα and RORγ with high affinity, altered the LBD conformation and reduced coactivator binding resulting in suppression of the constitutive transcriptional activity of these two receptors [52]. They recently reported that the two RORs also bind 24(S)-OHC (cerebrosterol), a brain-derived oxysterol, with high affinity, and that 24(S)-OHC functions as a RORα/γ inverse agonist suppressing the constitutive transcriptional activity of these receptors in cotransfection assays [53]. The authors also noted that 24(S),25-EPOX selectively suppressed the activity of RORγ. Interestingly, Wada et al. [54] found that RORα up-regulates expression of CYP7B1, which encodes oxysterol 7α-hydroxylase, an enzyme with a crucial role in bile acid synthesis and cholesterol metabolism. The authors also discovered that LXR target genes are induced in RORα-knock out mice and vice versa, suggesting a mutually suppressive function of these nuclear receptors. These findings indicate that RORα and RORγ serve as novel sensors for oxysterols and display an overlapping ligand preference and functional cross-talk with the LXR, suggesting the presence of an intriguingly complex sterol-controlled network of gene regulatory actions related with metabolic disease and atherosclerosis.

3. Oxysterols in Signaling and Development

3.1. Modulation of Hedgehog Signaling by Oxysterols

The Hedgehog (Hh) signaling pathway plays a central role in the patterning of metazoan embryos, in post-embryonic development, as well as in the homeostasis of adult tissues and stem cell physiology [55,56]. In 2006, the first evidence suggesting that cholesterol or certain oxysterols are required for Sonic hedgehog pathway signal transduction and proliferation of medulloblastoma cells was published by Corcoran and Scott [57]. Dwyer et al. [58] soon demonstrated that the oxysterols 20(S)- and 22(S)-OHC exert osteoinductive effects through activation of the Hh signaling pathway. Consistently, Kim et al. [59] provided evidence that the inhibition of bone marrow stromal cell differentiation into adipocytes by 20(S)-OHC occurs through a Hh-dependent mechanism, and later similar results have been reported with structural analogues of 20(S)-OHC [60]. In addition to activating the Hh signaling pathway, oxysterol-induced osteogenic differentiation was reported to be mediated through a Wnt signaling-related mechanism [61]. Furthermore, 20(S)-OHC was shown to activate Notch target genes, but apparently via a non-canonical mechanism, which may involve the LXR [62]. These findings have established a novel role of oxysterols as regulators of mammalian development. The recent report by Nachtergaele et al. [63] addresses the so far unidentified molecular mechanisms mediating the oxysterol impact on Hedgehog signaling: They found that the most potent
oxysterol, 20(S)-OHC, acts as an allosteric activator of the trans-membrane protein Smoothened, which mediates the signal upon induction by Hedgehog ligands.

3.2. 27-Hydroxycholesterol Modulates Estrogen Receptor Function

Estrogen receptors are nuclear receptors that, in addition to central functions in reproductive biology, mediate estrogen regulation of a number of other physiologic processes [64]. The cardiovascular protection observed in pre-menopausal females has been largely attributed to beneficial effects of estrogen on endothelial function and the lipid profile [65,66]. Umetani et al. [67] discovered that 27-OHC antagonizes the estrogen-dependent production of NO by vascular cells, resulting in reduced vasorelaxation of aorta, a potentially deleterious effect. Moreover, increasing 27-OHC levels repressed carotid artery re-endothelialization. Also cell type-specific pro-estrogenic actions of 27-OHC were reported [67,68], indicating that this oxysterol acts as an endogenous selective estrogen receptor modulator (SERM). Through its actions on both estrogen receptors and liver X receptors, 27-OHC decreases osteoblast differentiation and enhances osteoclastogenesis, resulting in increased bone resorption in mice [69,70]. Furthermore, the action of 27-OHC on estrogen receptors has been putatively linked with breast cancer: A decrease in the expression of E-cadherin and β-catenin, paralleling the loss of adherens junction complex, was observed in MCF7 breast cancer cells exposed 27-OHC, indicating an epithelial-mesenchymal transition characteristic of tumor development [71]. The findings suggest that 27-OHC may counteract the estrogen protection from vascular disease, impair the bone homeostasis, and possibly modify oncogenesis in estrogen receptor-dependent cancers, thus revealing novel, potentially harmful oxysterol functions.

4. Oxysterol-Induced Cell Death

Oxysterols are incorporated into biological membranes, and different oxysterols have distinct impacts on membrane lipid packing and especially on the cholesterol-sphingolipid-enriched raft domains with key roles in a number of signal transduction events [72,73]. Modification of membrane biophysical/biochemical properties by oxysterols thus most likely plays an important role in cytotoxicity elicited by these compounds (reviewed by Olkkonen and Hynynen, [74]). However, much of the cytotoxicity attributable to oxysterols is due to their ability to induce apoptosis, an aspect that has been extensively reviewed by Lordan et al. [11]. The two major apoptotic pathways are the mitochondrial (intrinsic) and the death receptor (extrinsic) pathways. Both pathways finish at the execution phase initiated by the activation of effector caspases, which in turn activate endonucleases degrading nuclear material and proteases that break down nuclear and cytoskeletal proteins. Caspase-3, -6, and-7 act as effector caspases at this stage, cleaving a variety of substrates such as poly(ADP-ribose) polymerase (PARP), resulting in the biochemical and morphological manifestations characterizing apoptotic cells [75]. Oxysterols can induce apoptosis by both pathways, and caspase-3, considered the most important effector caspase, is involved in apoptotic processes induced by a variety of oxysterols in different cell types (reviewed by Lordan et al., [11]). However, the distinct oxysterols vary greatly in their ability to induce apoptosis, and also the pathways employed by distinct oxysterols are different. Therefore, there is most likely no universal mechanism responsible for oxysterol-induced apoptosis. When considering the cytotoxic activity of oxysterols, it is important to realize that most
studies on the topic have been carried out by applying pure oxysterols on cultured cells. However, when oxysterols are administered as natural-like mixtures, as fatty acid esters, or as incorporated into lipoproteins, their cytotoxicity is strongly alleviated [76–79].

4.1. Death Receptor Pathway

Although there is only limited evidence to activation of the death receptor pathway by oxysterols, certain oxysterols are suggested to induce apoptosis via this route: Lee and Chau [80] demonstrated that 7β- and 25-OHC caused up-regulation of Fas and FasL (Fas ligand) and apoptosis of smooth muscle cells (SMCs) of vascular origin. This finding was supported by the study of Lordan et al. [81] showing that Fas inhibition reduced apoptosis of 7β-OHC-treated cells, and furthermore, that treatment with 7-KC predisposed human aortic SMC to Fas-mediated apoptotic cell death.

Oxysterols have in certain cases connected also with tumor necrosis factor (TNF)-α induced apoptotic processes. Lee et al. [82] demonstrated that 7-KC treatment of SMCs resulted in TNF receptor-mediated cell death. It is to some extent unclear whether oxysterols in general have the capacity to induce TNF-α expression and secretion. There is evidence for such induction by 22-OHC and 7β-OHC in human monocytes and THP-1 macrophages [83,84]. However, there is also contradicting data from macrophages [85], and 7β-OHC or 7-KC induced apoptosis of human endothelial cells was not associated with enhanced TNF-α secretion [86].

4.2. Mitochondrial Pathway of Apoptosis

Alterations in mitochondrial transmembrane potential in response to various triggering factors result in the production of reactive oxygen species (ROS) or to mitochondrial membrane permeabilization. This permeabilization can be induced by the proapoptotic Bak/Bax proteins, the interaction of which with voltage-dependent anion channel/adenine nucleotide transporter results in the release of small molecules, such as cytochrome c, apoptosis-inducing factor (AIF), endonuclease G, and smac/DIABLO, activating both caspase-dependent and –independent cell death pathways [87]. Loss of mitochondrial membrane potential and release of cytochrome c upon oxysterol treatment has been documented in many studies (reviewed by Lordan et al., [11]). It is important to note that different apoptotic pathways are induced dependent on the specific oxysterol(s) and the cell type employed; For instance, Ryan et al. [88] showed that in U937 cells, inhibition of cytochrome c release inhibited apoptosis induced by 7β-OHC but not by β-EPOX. Ghelli et al. [89] showed that in ECV304 cells treated with 7-KC no cytochrome c release was associated with the observed loss of cell viability. More mechanistic insight has been gained from recent studies: Kim and Lee [90] provided evidence that the tyrosine kinase inhibitor AG126 reduced 7-KC-induced cell death by suppressing mitochondrial permeability change, apparently via inhibition of ROS generation and GSH (glutathione) depletion. On the other hand, Gao et al. [91] demonstrated that apoptosis of J774 macrophage induced by the oxysterol cholesterol secoaldehyde (3β-hydroxy-5-oxo-5,6-secocholestan-6-al) is mediated via the mitochondrial pathway but without involvement of ROS.

Initiation of mitochondrial apoptotic pathway may result from activation of the pro-apoptotic Bak/Bax proteins and concomitant inactivation of the anti-apoptotic Bcl-2 family proteins such as Bcl-2 and Bcl-xL [92]. While some studies have documented oxysterol impacts on the balance of
cellular Bax vs. Bcl-2/Bcl-xL levels [93–95], no such effect was seen in 7β-OHC-treated Caco-2 cells [96], suggesting involvement of a Bax/Bcl-2 independent apoptotic process. Lordan et al. [97] presented evidence that increase of cytosolic Ca²⁺ concentration may be an early trigger of 7β-OHC-induced apoptosis in U937 cells—however, it did not seem to play a role in β-EPOX-induced apoptosis. These observations illustrate well the variability in the pathways of cell death induced by different oxysterols in different model systems employed.

4.3. Protein Kinases Involved in Oxysterol-Induced Cell Death

A variety of protein kinases have been implicated in both the upstream induction phase of apoptosis and as targets of caspases during the actual execution of the apoptosis process, but also in other modes of cell death. The kinases implicated in apoptosis belong to mitogen activated protein kinase (MAPK), Akt/PKB, and the protein kinase C families (reviewed by Lordan et al., [11]). Anticoli et al. [98] reported that 7-KC and 5,6-secosterol modulate differently the stress-activated MAPKs in liver cells: Pathologic concentrations of both oxysterols induced necrosis of the cells after 48 h treatment. 5,6-secosterol, but not 7-KC, induced cell senescence at high concentrations, but caused sustained ERK1/2 (extracellular signal activated kinases) activation and cellular proliferation at low concentrations. 7-KC was reported to induce apoptosis of PC12 neuroendocrine cells via ROS-mediated activation of NF-κB and Akt/PKB pathways [99]. Consistently, Liu et al. [100] found that lanthanum chloride suppresses cholestan-3β,5α,6β-triol induced apoptosis of ECV-304 cells via inhibition of ERK and NF-κB activation. Further, Laynes et al. [101] reported that inhibitors of p38 MAPK, ERK1/2 and JNK (Jun N-terminal kinase) suppressed the cytotoxicity of cholesterol secoaldehyde (ChSeco) in H9c2 cardiomyoblasts. ChSeco is known to induce apoptosis by both intrinsic and extrinsic pathways, and the above study suggested the involvement of ROS such as hydrogen peroxide in the ChSeco cytotoxicity.

5. Oxysterols in Inflammation and Immunity

5.1. Oxysterols as Immune Modulators

A number of reports have demonstrated the capacity of exogenously administered oxysterols, mainly 7-KC, 7β-OHC and 25-OHC, to enhance expression of inflammatory mediators, such as IL-8 and MCP-1, by macrophages [84,85,102] and other cell types not belonging to professional immune cells [86,103–105]. Importantly, endogenous 25-OHC has been shown to be secreted by dendritic cells and macrophages in response to Toll-like receptor activation, the cholesterol 25-hydroxylase (CH25H) gene expression being regulated by type I interferons via signaling through the interferon-α receptor and the JAK/STAT1 pathway [106,107]. The secreted 25-OHC was shown to suppress IgA class switching in B-cells, demonstrating a crucial function of endogenous 25-OHC in immunity control [106]. On the same theme, two recent studies identified the orphan G-protein coupled receptor EBI2 (Epstein-Barr virus induced gene 2) as a cell surface oxysterol receptor that directs B-cell migration [108,109]. 7α,25-dihydroxycholesterol generated from 25-OHC by oxysterol 7α-hydroxylase CYP7B1 was identified as the most potent ligand of this receptor. The data shows the potency of endogenous oxysterols as immune regulators, and brings up the idea that oxysterols or their synthetic
analogs could offer therapeutic benefits either as adjuvants of immune modulators in the treatment of inflammation or autoimmune diseases.

5.2. Inflammatory Functions and the LXR

Increasing evidence demonstrates the ability of the LXR, presumably as liganded by endogenous cellular oxysterols, to down-regulate inflammatory signaling (reviewed by Calkin and Tontonoz, [24]). Joseph et al. [23] first showed that LXR activation attenuated the expression of IL-6, iNOS (inducible nitric oxide synthase) and COX-2 (cyclooxygenase 2) in macrophages stimulated with E. coli or lipopolysaccharide. Moreover, the LXR were shown to down-regulate the expression of matrix metalloproteinase 9 (MMP-9), a protease abundant in the macrophage-rich regions of atherosclerotic lesions and apparently plays a role in extracellular matrix degradation and plaque destabilization [23,110]. The anti-inflammatory effects of the LXR have been attributed to their ability to dampen the activity of NF-κB, which controls expression of all of the genes mentioned above, via a mechanism designated transrepression [111]. More recent studies have demonstrated the cross-talk of LXR with multiple Toll-like receptors (TLR): TLR3/4 stimulation was shown to suppress LXR signaling [112], and the LXR were reported to dampen atherogenic signaling via the TLR2/TLR4/MyD88 route [113]. Moreover, activation of the macrophage LXR by apoptotic cells was shown to enhance apoptotic cell clearance with simultaneous down-regulation of inflammatory signals [114]. Importantly, Bensinger et al. [115] also showed that LXR signaling couples the cellular sterol metabolism, via regulation of ABCG1 (cholesterol transporter) expression, with T-cell proliferation in acquired immune response. These investigations have revealed that the LXR control of number of immune and inflammatory pathways that play important roles in the development of atherosclerosis, and underscore that potential value of the LXR as future therapeutic targets.

6. Niemann-Pick C1 Protein and StarD5 Bind Both Cholesterol and 25-OHC

Niemann-Pick C (NPC) disease is characterized by accumulation of free cholesterol and sphingolipids within late endocytic compartments of cells [116]. The disease is caused by mutations in either of two proteins designated NPC1 or NPC2. NPC1, mutations of which account for a majority of the disease, is a multi-spanning membrane protein localized in late endosomes, and has a consensus cholesterol binding motif consisting of five trans-membrane helices. The mechanism by which NPC1 facilitates egress of lipids from late endocytic compartments is poorly understood, but it seems to receive cholesterol from the NPC2 protein localizing in endosome lumen [117] and was recently suggested to donate it to the OSBP homologue ORP5 (see section 7; [118]). Interestingly, NPC1 was found to bind not only cholesterol but also 25-OHC, the binding of which was efficiently competed by 24(S)-OHC and 27-OHC [119]. The authors found that cholesterol and 25-OHC bind not to the trans-membrane helix motif but to a luminal loop of NPC1 [120]. However, in further experiments it seemed that the oxysterol binding may not be involved in the classical function of NPC1 in mediating cholesterol transport.

StarD5, a cytoplasmic protein belonging to the family of proteins carrying a steroidogenic acute regulatory protein (StAR)-related lipid transfer (START) domain [121], was shown to bind both cholesterol and 25-OHC [122]. Although the physiologic function of StarD5 is poorly understood,
it was shown to enhance steroidogenesis in an in vitro assay, evidencing for its ability to transfer cholesterol [123]. As for NPC1, the functional role of 25-OHC binding by StarD5 remains unclear.

7. The Cytoplasmic Oxysterol-Binding Proteins—Functions in Lipid Metabolism and Sterol-Dependent Signaling

Families of proteins with sequence homology to the cytoplasmic oxysterol-binding protein, OSBP, are present throughout the eukaryotic kingdom. In mammals the family consists of 12 members. These proteins, designated OSBP-related (ORP) or OSBP-like (OSBPL) proteins, have been implicated in a variety of functions involving cellular lipid metabolism, vesicle transport, and cell signaling (reviewed by Vihervaara et al., [124]). However, the mechanisms of their action have remained poorly understood. Furthermore, many family members have, in addition to oxysterols, been found to bind cholesterol, which is far more abundant in cells. Hence, the identity of the true physiologic ligands of the ORP proteins is not fully solved. In the following we summarize the most important findings on ORP function.

7.1. OSBP Regulates Cellular Lipid Homeostasis

OSBP, the founder member of the ORP family, acts as a sterol sensor involved in the regulation of sphingomyelin synthesis via control of the localization and activity of PtdIns-4-kinase IIα and ceramide transporter, CERT, responsible for non-vesicular transport of ceramides from the endoplasmic reticulum (ER) to Golgi where sphingomyelin synthase is located [125,126]. Adenoviral overexpression of rabbit OSBP in mouse liver was shown to result in an increase of plasma very-low-density lipoprotein (VLDL) and liver tissue triglycerides (TG) [127]. Analysis of the underlying mechanism revealed up-regulation of SREBP-1c expression and increase of the active nuclear form of this lipogenic transcription factor in the liver of mice injected OSBP-expressing adenovirus. Silencing of OSBP by RNA interference in cultured hepatocytes attenuated the insulin induction of SREBP-1c and fatty acid synthetase (FAS), as well as TG synthesis. Furthermore, OSBP overexpression was shown to inhibit phosphorylation of the ERKs. In the light of the finding that changes in ERK activity impact the stability of nuclear SREBP-1c [128], this provides one tentative mechanistic explanation to the OSBP overexpression phenotype: Its impact of ERK could modify the stability of nuclear SREBP-1c and thereby hepatic lipogenesis and VLDL secretion. The findings demonstrate a role of OSBP as a sterol-dependent regulator sphingomyelin synthesis and hepatic TG metabolism, as well as a putative function in insulin-induced signaling cascades.

Bowden and Ridgway [129] reported that silencing of OSBP by RNA interference resulted in increased cellular amount and cholesterol efflux activity of ABCA1, in the absence of effects on the ABCA1 mRNA level or LXR activity. OSBP knock-down was shown to increase the half-life of the ABCA1 protein, the effect being dependent on an intact OSBP sterol-binding domain. Thus, it seems that OSBP opposes the activity of LXR by destabilizing ABCA1.
7.2. Roles for OSBP in ERK and JAK-2/STAT3 Signaling, Amyloid Precursor Protein Processing, and Hepatitis C Virus Assembly

R. Anderson’s group (Wang et al. [130,131]) identified OSBP as a sterol-sensing scaffolding factor that regulates the dephosphorylation and hence the activity of the ERK, important components of the mitogen activated protein kinase (MAPK) signaling pathways. Romeo and Kazlauskas [132] found that up-regulation of profilin-1, an actin-binding protein implicated in endothelial dysfunction and atherosclerosis, by 7-KC is mediated by OSBP. The signaling route involves interaction of the OSBP-7-KC complex with the tyrosine kinase JAK-2, which phosphorylates Tyr394 on OSBP. This apparently leads to the activation of STAT3, which induces profilin. An important implication of these findings is that also other members of the ORP family could act as lipid sensors with scaffolding functions in cell signaling. Consistent with this idea, Lessman et al. [133] demonstrated that ORP9 contains a phosphoinositide-dependent kinase-2 (PDK-2) phosphorylation site, the phosphorylation of which is dependent on PKC-β or mTOR. ORP9 was shown to interact with these kinases to negatively regulate phosphorylation of the PKD-2 site in Akt/protein kinase B, a major controller of cell survival, cell cycle progression, and glucose metabolism.

Zerbinatti et al. [134] demonstrated that OSBP overexpression in a neuroglioma cell line and in HEK293 cells down-regulated the processing of amyloid precursor protein (APP) to β-amyloid (Aβ); OSBP silencing had the opposite effect. OSBP overexpression resulted in the sequestration of APP-Notch2 heterodimers in the Golgi complex, an effect reversed by addition of the OSBP high-affinity ligand 25-OHC. This is consistent with the established findings that the distribution of OSBP itself between cytosol/ER and Golgi membranes is regulated by the cellular sterol status [135,136], and suggests that OSBP modulates the intracellular trafficking of APP. OSBP could thus play a pivotal role in controlling APP metabolism in a sterol-dependent fashion.

Localization of OSBP in the Golgi complex is negatively regulated by protein kinase D (PKD)-mediated phosphorylation [137]. OSBP was shown to interact in the Golgi complex with the Hepatitis C virus (HCV) non-structural protein NS5A, and OSBP silencing inhibited secretion of HCV particles by infected cells [138]. Moreover, HCV release was shown to be suppressed by PKD, an effect mediated by phosphorylation of OSBP and its functional partner, CERT [139]. A further implication of OSBP-mediated lipid regulation of microbial infection is provided by the study of Auweter et al. [140] suggesting that OSBP enhances Salmonella replication. As a conclusion, there is increasing evidence for pleiotropic functions of OSBP as a modulator of signaling and intracellular transport events. These properties make OSBP a target that is highjacked by micro-organisms to facilitate their intracellular replication and progeny release.

7.3. ORP8 and the Transcriptional Control of Lipid Metabolism

Related with the above report on OSBP, Yan et al. [141] demonstrated that silencing of ORP8 expression in THP-1 macrophages induces the transcription of ABCA1 and, consequently, cholesterol efflux to apolipoprotein A-I. This effect was reproduced using a luciferase reporter assay, in which ORP8 silencing synergized with a synthetic LXR agonist and was significantly suppressed when a mutant ABCA1 promoter devoid of a functional LXR response (DR4) element was used, providing the
first solid piece of evidence for a functional interplay between the LXR and the ORPs. Importantly, ORP8 was found to be abundant in the macrophages of human coronary artery lesions, bringing up the possibility that ORP8 may play a role, possibly an adverse one, in the development of atherosclerotic lesions. Our recent work employing mouse macrophage models indicates that the modulation of ABCA1 expression upon ORP8 silencing or knock-out is weak and is most likely mediated by an indirect mechanism (unpublished observations).

We recently found that ORP8 overexpression in mouse liver results in a reduction of plasma and liver tissue lipid levels, associated with down-regulation of the active, nuclear forms of SREBP-1 and -2 [142]. Moreover, ORP8 was found to physically interact with the nuclear pore complex component NUP62, and a normal level of NUP62 in HuH7 hepatoma cells was found to be necessary for the ORP8-mediated reduction of nuclear SREBPs. These findings indicated that ORP8 has the capacity to modulate SREBP-dependent transcription, and it may affect the activity of several transcription factors systems, possibly via an indirect mechanism involving the nuclear pore complex and transport of transcription factors and other nuclear components in and out of the nucleus.

### 7.4. ORP1L Regulates Late Endosome Motility and Macrophage Lipid Metabolism

Johansson et al. [143] employed ORP1L knock-down to show that the protein is required for the clustering of late endocytic compartments in the pericentriolar region. The protein was shown to form a complex with the late endosomal GTPase Rab7 and its second effector protein RILP. The tripartite complex apparently recruits dynein/dynactin motor to late endosome (LE) membranes to drive minus-end directed motility of the compartments. In a recent study we demonstrated how ligand interactions regulate ORP1L function [144]. By deleting four amino acids from the lid of ORP1L ORD we created a mutant deficient in binding oxysterols (ORP1L Δ560–563). This mutation did not result in translocation of the protein from the LE, but the distribution of LE changed dramatically. Whereas the wild-type (WT) protein induced LE clustering, the LE decorated by mutant ORP1L displayed a scattered phenotype. Similar LE scattering was recently achieved by cellular cholesterol depletion, and ORP1L was shown to be key mediator of the effect [145]. A double mutant deficient in sterol binding and containing a disrupted ER-targeting two phenylalanines in an acidic tract (FFAT) motif (ORP1L Δ560–563 mFFAT) induced LE clustering, demonstrating that destruction of the ER interaction of ORP1L reversed the scattered LE phenotype [144]. A model arising from these experiments and those of Rocha et al. [145] is that non-sterol bound ORP1L bridges between Rab7 on LE and VAPs in the ER, thus forming a membrane contact site (see Levine and Loewen, [146]), which is likely to restrict LE motility; Silencing of ORP1L increased the motility of LE and late endosomal tracks had a more peripheral distribution, probably due to impairment of dynein/dynactin recruitment, or to an altered balance between the minus- and plus-end directed motor complexes.

Yan et al. [147] showed that transgenic macrophages overexpressing ORP1L increased the size of atherosclerotic lesions in LDL receptor deficient mice. The transgenic macrophages displayed a defect in cholesterol efflux to spherical high-density lipoproteins (HDL) and reduced expression of ABCG1 and apolipoprotein E, as well as increased expression of phospholipid transfer protein (PLTP). All these genes are subject to transcriptional regulation by the LXRs. Furthermore, ORP1L overexpression in cultured macrophages was shown to attenuate the response of the ABCG1 mRNA to the LXR
agonist 22(R)OHC, which is also a ligand of ORP1L. The work of Vihervaara et al. [144] showed that ORP1L silencing in mouse Raw264.7 macrophage inhibited the efflux of endocytosed lipoprotein cholesterol to apolipoprotein A-I, thus presumably affecting ABCA1-dependent cholesterol transport. One interpretation of these results is that ORP1L could modulate the LXR ligand interactions, thereby affecting the expression of LXR target genes and the development of atherosclerosis. However, it is also possible that other, more indirect mechanisms account for the observed phenotypic effect.

7.5. Sterol Transporter Function of ORPs

Evidence for ORP function in actual sterol transport was reported by the groups of W. Prinz and A. Menon: Raychaudhuri et al. showed that the Saccharomyces cerevisiae ORP Osh4p is able to extract sterols from liposomes and to deliver them to acceptor membranes. Cells deficient of all seven Osh proteins displayed a marked, 80% reduction in the transfer of cholesterol or ergosterol from plasma membrane (PM) to ER [148]. Involvement of Osh proteins was also suggested in transfer of newly synthesized ergosterol from ER to PM; depletion of all 7 Osh proteins reduced the rate of this transport 5-fold [149]. However, the group of A. Menon recently reached the opposite conclusion: They provided evidence that the role of Osh proteins in ER to PM ergosterol transport is minor, and that Osh protein defect rather distorts the sterol organization in the plasma membrane [150].

Of the mammalian ORPs, OSBP, ORP9L, and the ORP5 ORD have been shown to transfer cholesterol between membranes in vitro [118,151]. Silencing of ORP5, which is anchored to ER membranes, was shown to cause cholesterol accumulation to the limiting membrane of late endosomes. The protein was demonstrated to associate with NPC1, consistent with a model in which ORP5 accepts cholesterol from NPC1 and routes it to the ER [118]. Jansen et al. [152] recently provided evidence that mammalian ORPs have the capacity to stimulate cholesterol transfer in live cells. They used an assay to monitor the transport of a Bodipy-labeled cholesterol derivative from the PM to lipid droplets (LD), and studied the contribution of ORP overexpression to the process. In this study, out of all human ORPs, overexpression of two ORPs of the short subtype, ORP1S and ORP2, gave the largest increase in sterol transport, and silencing both of them simultaneously decreased the transport rate [152]. The effect of the ORPs was further localized to the PM-ER transport step, whereas the rapid ER-LD sterol transport was unaffected by ORP manipulation. In addition, a functional sterol-binding pocket was shown to be necessary for the observed transport enhancement in the case of ORP2. The finding that the PM to ER sterol transfer was most affected by the short ORPs, ORP1S and ORP2, could reflect the ability of these proteins, devoid of PH domains, to associate and dissociate from membranes more rapidly than the long ORPs, perhaps allowing more efficient shuttling between donor and acceptor membranes. This study supports a role for ORPs in sterol transfer but like the studies on yeast Osh proteins, does not provide conclusive evidence for a sterol carrier function. One cannot exclude the possibility that the role of ORP sterol binding might be regulatory, and the observed impacts on sterol trafficking indirect, for instance via the control of membrane contact site formation or the function of other proteins at such sites (reviewed in Levine and Loewen, [146]). Alternatively, modulation of membrane lipid composition by ORPs could affect the ability of membranes to accommodate sterols and thereby alter sterol fluxes, as suggested by Georgiev et al. [150].
7.6. ORP3 Regulates Cell Adhesion

ORP3 and ORP7 were found to interact physically with R-Ras, a small GTPase that regulates cell adhesion and migration [153], implying a role of these ORPs in R-Ras signaling. Lehto et al. [154] reported that ORP3 controls cell adhesion and spreading, organization of the actin cytoskeleton, β1-integrin activity and macrophage phagocytic function, cellular processes also subject to regulation by R-Ras. Furthermore, ORP3 phosphorylation was suggested to be regulated by outside-in signals mediated by integrins and cadherins. ORP3 is expressed abundantly in leukocytes and in several epithelia, and its abnormally high expression is detected in certain forms of leukemia and solid tumors, suggesting that the protein may modify cell signaling and adhesion properties in a manner that facilitates malignant growth.

7.7. S. cerevisiae Osh4p Modulates the Golgi Phosphatidylinositol-4-Phosphate Pool and Secretory Vesicle Transport

Deletion of the S. cerevisiae ORP OSH4/KES1 leads to by-pass of the temperature-sensitivity of mutants in SEC14, a gene encoding a phosphatidylinositol transfer protein (PITP; Sec14p) essential for secretory vesicle biogenesis [155,156]. Osh4p thus acts as a negative regulator of Golgi secretory function, but the underlying mechanism has remained poorly understood. The group of C. McMaster showed that Osh4p reduces both the cellular content of phosphatidylinositol-4 phosphate (PI4P) and its availability for recognition by other proteins, which include components required for transport vesicle formation [157]. Interestingly, Alfaro et al. [158] recently found a direct role for Osh4p in exocytic vesicle transport: They showed that Osh4p associated with exocytic vesicles that move from the mother cell into the bud, where Osh4p facilitated vesicle docking by the exocyst tethering complex at sites of polarized growth on the plasma membrane. Osh4p formed complexes with the small GTPases Cdc42p, Rho1p and Sec4p, and the exocyst complex subunit Sec6p, which was also required for Osh4p association with vesicles. Although Osh4p directly affected polarized exocytosis the relationship of this function with that in sterol trafficking remained unclear. Importantly, de Saint-Jean et al. [159] recently made the ground-breaking finding that Osh4p, in addition to sterols, binds also PI4P employing the same binding pocket. It is able to exchange bound sterol for PI4P and transport the two lipids between membranes along opposite routes. The results suggest a model in which Osh4p transports sterol from the ER to late compartments and, in turn, PI4P backward from trans-Golgi and plasma membrane to the ER. This transport cycle would create a sterol gradient, promoting sterol enrichment in membranes of the late secretory pathway, and play a role in controlling the concentration and distribution of PI4P, with an essential function in secretory vesicle transport.

8. Future Perspectives

Oxysterols were previously considered to represent harmful substances that accumulate in pathophysiologic states. However, work carried out during the past decade has revealed their physiologic functions as signaling molecules that maintain cellular and body lipid homeostasis and determine cell fate. The discovery of oxysterol interactions with new receptors involved in lipid metabolism, such as the LXRs, Insigs, RORs, the estrogen receptors, NPC1, StarD5 and the OSBP-related proteins, paves
the way for future work to elucidate in detail the mechanisms of oxysterol action in lipid metabolism and in diseases such as atherosclerosis and Alzheimer’s disease. Discovery of oxysterols as regulators of Hedgehog signaling uncovered their role in embryonic development, and the recent finding on oxysterol liganding of EBI2 pinpoints a novel effector route for regulation of immunity. These observations have shed light on the diversity of oxysterol activities and opened new perspectives in oxysterol research: With developing oxysterol analytical methodologies and advanced approaches of in vivo genetic manipulation of various organisms and cells in culture, we can expect a plethora of novel connections of oxysterols and their cellular receptors regimes such as differentiation, development, and immunity. The currently known major functions of oxysterols are summarized in Figure 2. The major functions of cellular oxysterol receptors are summarized in Table 2.

**Figure 2.** A schematic presentation summarizing the major functions of oxysterols. ROR, retinoic acid receptor-related orphan receptor; OSBP, oxysterol-binding protein; ORP, OSBP-related protein; LXR, liver X receptor; SREBP, sterol regulatory element binding protein; Insig, insulin-induced gene; ROS, reactive oxygen species; Bcl-2, B-cell lymphoma 2; IgA, immunoglobulin A; CNS, central nervous system.
Table 2. Cellular receptors for oxysterols.

| Receptor (or rec. family) | Function                                                                 | References          |
|---------------------------|--------------------------------------------------------------------------|---------------------|
| LXRα, LXRβ                | Transcriptional regulation of cholesterol adsorption and cellular efflux, cholesterol and bile acid synthesis, neutral lipid secretion into bile, inflammation and immune response | [22*,24*]           |
| OSBP/ORPs                 | Regulation of lipid homeostasis, vesicle transport and cell signaling     | [124*]              |
| Insig                     | Regulation of SREBP maturation; cholesterol and fatty acid biosynthesis and LDL receptor expression | [36,37]             |
| StarD5                    | Cellular cholesterol metabolism and transport; up-regulated upon ER stress | [121*,122]          |
| NPC1                      | Egress of endocytosed cholesterol out of late endocytic compartments      | [119,120]           |
| RORα, RORγ                | Transcriptional regulation of genes involved in development, metabolism, and immunity | [52,53]             |
| EBI2/GPR183               | Control of B-cell migration                                              | [108,109]           |
| SMOOTHENED                | Hedgehog signaling                                                      | [63]                |

* The indicated references are review articles included to avoid excessive listing of literature

Acknowledgments

Work in the authors’ group is supported by the Academy of Finland (grant 121457), the Sigrid Juselius Foundation, the Finnish Foundation for Cardiovascular Research, the Novo Nordisk Foundation, the Liv och Hälsa Foundation, the Magnus Ehrnrooth Foundation, and the European Union FP7 (LipidomicNet, agreement no. 202272).

References

1. Björkhem, I.; Diczfalusy, U. Oxysterols: Friends, foes, or just fellow passengers? Arterioscler. Thromb. Vasc. Biol. 2002, 22, 734–742.
2. Olkkonen, V.M. Oxysterols and oxysterol-binding proteins in cellular lipid metabolism. In Cellular Lipid Metabolism; Ehnholm, C., Ed.; Springer: Heidelberg, Germany, 2009, pp. 27–71.
3. Schroepfer, G.J., Jr. Oxysterols: Modulators of cholesterol metabolism and other processes. Physiol. Rev. 2000, 80, 361–554.
4. Russell, D.W. Oxysterol biosynthetic enzymes. Biochim. Biophys. Acta 2000, 1529, 126–135.
5. Luoma, P.V. Cytochrome P450—Physiological key factor against cholesterol accumulation and the atherosclerotic vascular process. Ann. Med. 2007, 39, 359–370.
6. Björkhem, I. Rediscovery of cerebrosterol. Lipids 2007, 42, 5–14.
7. Björkhem, I.; Eggertsen, G. Genes involved in initial steps of bile acid synthesis. Curr. Opin. Lipidol. 2001, 12, 97–103.
8. Babiker, A.; Andersson, O.; Lund, E.; Xiu, R.J.; Deeb, S.; Reshef, A.; Leitersdorf, E.; Diczfalusy, U.; Björkhem, I. Elimination of cholesterol in macrophages and endothelial cells by the sterol 27-hydroxylase mechanism. Comparison with high density lipoprotein-mediated reverse cholesterol transport. *J. Biol. Chem.* 1997, 272, 26253–26261.

9. Bodin, K.; Andersson, U.; Rystedt, E.; Ellis, E.; Norlin, M.; Pikuleva, I.; Eggertsen, G.; Björkhem, I.; Diczfalusy, U. Metabolism of 4 beta-hydroxycholesterol in humans. *J. Biol. Chem.* 2002, 277, 31534–31540.

10. Brown, A.J.; Jessup, W. Oxysterols and atherosclerosis. *Atherosclerosis* 1999, 142, 1–28.

11. Lordan, S.; Mackrill, J.J.; O’Brien, N.M. Oxysterols and mechanisms of apoptotic signaling: Implications in the pathology of degenerative diseases. *J. Nutr. Biochem.* 2009, 20, 321–336.

12. Olkkonen, V.M.; Lehto, M. Oxysterols and oxysterol binding proteins: Role in lipid metabolism and atherosclerosis. *Ann. Med.* 2004, 36, 562–572.

13. Shibata, N.; Glass, C.K. Macrophages, oxysterols and atherosclerosis. *Circ. J.* 2010, 74, 2045–2051.

14. Vejux, A.; Samadi, M.; Lizard, G. Contribution of cholesterol and oxysterols in the physiopathology of cataract: Implication for the development of pharmacological treatments. *J. Ophthalmol.* 2011, 2011, doi:10.1155/2011/471947.

15. Wang, D.Q.; Afdhal, N.H. Good cholesterol, bad cholesterol: Role of oxysterols in biliary tract diseases. *Gastroenterology* 2001, 121, 216–218.

16. Javitt, N.B.; Javitt, J.C. The retinal oxysterol pathway: A unifying hypothesis for the cause of age-related macular degeneration. *Curr. Opin. Ophthalmol.* 2009, 20, 151–157.

17. Jeitner, T.M.; Voloshyna, I.; Reiss, A.B. Oxysterol derivatives of cholesterol in neurodegenerative disorders. *Curr. Med. Chem.* 2011, 18, 1515–1525.

18. Gill, S.; Chow, R.; Brown, A.J. Sterol regulators of cholesterol homeostasis and beyond: The oxysterol hypothesis revisited and revised. *Prog. Lipid Res.* 2008, 47, 391–404.

19. Janowski, B.A.; Willy, P.J.; Devi, T.R.; Falck, J.R.; Mangelsdorf, D.J. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. *Nature* 1996, 383, 728–731.

20. Lehmann, J.M.; Kliwer, S.A.; Moore, L.B.; Smith-Oliver, T.A.; Oliver, B.B.; Su, J.L.; Sundseth, S.S.; Winegar, D.A.; Blanchard, D.E.; Spencer, T.A.; Willson, T.M. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. *J. Biol. Chem.* 1997, 272, 3137–3140.

21. Fu, X.; Menke, J.G.; Chen, Y.; Zhou, G.; MacNaul, K.L.; Wright, S.D.; Sparrow, C.P.; Lund, E.G. 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. *J. Biol. Chem.* 2001, 276, 38378–38387.

22. Tontonoz, P.; Mangelsdorf, D.J. Liver X receptor signaling pathways in cardiovascular disease. *Mol. Endocrinol.* 2003, 17, 985–993.

23. Joseph, S.B.; Castrillo, A.; Laffitte, B.A.; Mangelsdorf, D.J.; Tontonoz, P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. *Nat. Med.* 2003, 9, 213–219.

24. Calkin, A.C.; Tontonoz, P. Liver x receptor signaling pathways and atherosclerosis. *Arterioscler. Thromb. Vasc. Biol.* 2010, 30, 1513–1518.
Biomolecules 2012, 2

25. Joseph, S.B.; McKilligin, E.; Pei, L.; Watson, M.A.; Collins, A.R.; Laffitte, B.A.; Chen, M.; Noh, G.; Goodman, J.; Hagger, G.N.; Tran, J.; Tippin, T.K.; Wang, X.; Lusis, A.J.; Hsueh, W.A.; Law, R.E.; Collins, J.L.; Willson, T.M.; Tontonoz, P. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. *Proc. Natl. Acad. Sci. USA* 2002, 99, 7604–7609.

26. Schuster, G.U.; Parini, P.; Wang, L.; Alberti, S.; Steffensen, K.R.; Hansson, G.K.; Angelin, B.; Gustafsson, J.A. Accumulation of foam cells in liver X receptor-deficient mice. *Circulation* 2002, 106, 1147–1153.

27. Schultz, J.R.; Tu, H.; Luk, A.; Repa, J.J.; Medina, J.C.; Li, L.; Schwendner, S.; Wang, S.; Thoolen, M.; Mangelsdorf, D.J.; Lustig, D.; Shan, B. Role of LXRαs in control of lipogenesis. *Genes Dev.* 2000, 14, 2831–2838.

28. Lo Sasso, G.; Murzilli, S.; Salvatore, L.; D’Errico, I.; Petruzelli, M.; Conca, P.; Jiang, Z.Y.; Calabresi, L.; Parini, P.; Moschetta, A. Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis. *Cell. Metab.* 2010, 12, 187–193.

29. Yasuda, T.; Grillot, D.; Billheimer, J.T.; Briand, F.; Delerive, P.; Huet, S.; Rader, D.J. Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo. *Arterioscler. Thromb. Vasc. Biol.* 2010, 30, 781–786.

30. Chen, W.; Chen, G.; Head, D.L.; Mangelsdorf, D.J.; Russell, D.W. Enzymatic reduction of oxysterols impairs LXR signaling in cultured cells and the livers of mice. *Cell Metab.* 2007, 5, 73–79.

31. Shafaati, M.; Olin, M.; Bavner, A.; Pettersson, H.; Rozell, B.; Meaney, S.; Parini, P.; Björkhem, I. Enhanced production of 24S-hydroxycholesterol is not sufficient to drive liver X receptor target genes in vivo. *J. Intern. Med.* 2011, 270, 377–387.

32. Eberle, D.; Hegarty, B.; Bossard, P.; Ferre, P.; Foufelle, F. SREBP transcription factors: Master regulators of lipid homeostasis. *Biochimie* 2004, 86, 839–848.

33. Goldstein, J.L.; DeBose-Boyd, R.A.; Brown, M.S. Protein sensors for membrane sterols. *Cell* 2006, 124, 35–46.

34. Adams, C.M.; Reitz, J.; De Brabander, J.K.; Feramisco, J.D.; Li, L.; Brown, M.S.; Goldstein, J.L. Cholesterol and 25-hydroxycholesterol inhibit activation of SREBPs by different mechanisms, both involving SCAP and Insigs. *J. Biol. Chem.* 2004, 279, 52772–52780.

35. Brown, A.J.; Sun, L.; Feramisco, J.D.; Brown, M.S.; Goldstein, J.L. Cholesterol addition to ER membranes alters conformation of SCAP, the SREBP escort protein that regulates cholesterol metabolism. *Mol. Cell* 2002, 10, 237–245.

36. Radhakrishnan, A.; Ikeda, Y.; Kwon, H.J.; Brown, M.S.; Goldstein, J.L. Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: Oxysterols block transport by binding to Insig. *Proc. Natl. Acad. Sci. USA* 2007, 104, 6511–6518.

37. Sun, L.P.; Seemann, J.; Goldstein, J.L.; Brown, M.S. Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: Insig renders sorting signal in Scap inaccessible to COPII proteins. *Proc. Natl. Acad. Sci. USA* 2007, 104, 6519–6526.

38. Lange, Y.; Ory, D.S.; Ye, J.; Lanier, M.H.; Hsu, F.F.; Steck, T.L. Effectors of rapid homeostatic responses of endoplasmic reticulum cholesterol and 3-hydroxy-3-methylglutaryl-CoA reductase. *J. Biol. Chem.* 2008, 283, 1445–1455.
39. Nelson, J.A.; Steckbeck, S.R.; Spencer, T.A. Biosynthesis of 24,25-epoxycholesterol from squalene 2,3;22,23-diole. J. Biol. Chem. 1981, 256, 1067–1068.

40. Janowski, B.A.; Shan, B.; Russell, D.W. The hypocholesterolemic agent LY295427 reverses suppression of sterol regulatory element-binding protein processing mediated by oxysterols. J. Biol. Chem. 2001, 276, 45408–45416.

41. Mark, M.; Muller, P.; Maier, R.; Eisele, B. Effects of a novel 2,3-oxidosqualene cyclase inhibitor on the regulation of cholesterol biosynthesis in HepG2 cells. J. Lipid. Res. 1996, 37, 148–158.

42. Janowski, B.A.; Grogan, M.J.; Jones, S.A.; Wisely, G.B.; Kliwer, S.A.; Corey, E.J.; Mangelsdorff, D.J. Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc. Natl. Acad. Sci. USA 1999, 96, 266–271.

43. Beyea, M.M.; Heslop, C.L.; Sawyez, C.G.; Edwards, J.Y.; Markle, J.G.; Hegele, R.A.; Huff, M.W. Selective up-regulation of LXR-regulated genes ABCA1, ABCG1, and APOE in macrophages through increased endogenous synthesis of 24(S),25-epoxycholesterol. J. Biol. Chem. 2007, 282, 5207–5216.

44. Rowe, A.H.; Argmann, C.A.; Edwards, J.Y.; Sawyez, C.G.; Morand, O.H.; Hegele, R.A.; Huff, M.W. Enhanced synthesis of the oxysterol 24(S),25-epoxycholesterol in macrophages by inhibitors of 2,3-oxidosqualene:lantosterol cyclase: A novel mechanism for the attenuation of foam cell formation. Circ. Res. 2003, 93, 717–725.

45. Wong, J.; Quinn, C.M.; Brown, A.J. Synthesis of the oxysterol, 24(S), 25-epoxycholesterol, parallels cholesterol production and may protect against cellular accumulation of newly-synthesized cholesterol. Lipids Health Dis. 2007, 6, doi:10.1186/1476-511X-6-10.

46. Wong, J.; Quinn, C.M.; Gelissen, I.C.; Brown, A.J. Endogenous 24(S),25-epoxycholesterol fine-tunes acute control of cellular cholesterol homeostasis. J. Biol. Chem. 2008, 283, 700–707.

47. Wong, J.; Quinn, C.M.; Guillemin, G.; Brown, A.J. Primary human astrocytes produce 24(S),25-epoxycholesterol with implications for brain cholesterol homeostasis. J. Neurochem. 2007, 103, 1764–1773.

48. Ouimet, M.; Wang, M.D.; Cadotte, N.; Ho, K.; Marcel, Y.L. Epoxycholesterol impairs cholesteryl ester hydrolysis in macrophage foam cells, resulting in decreased cholesterol efflux. Arterioscler. Thromb. Vasc. Biol. 2008, 28, 1144–1150.

49. Jetten, A.M. Retinoid-related orphan receptors (RORs): Critical roles in development, immunity, circadian rhythm, and cellular metabolism. Nucl. Recept. Signal. 2009, 7, doi:10.1621/nrs.07003.

50. Winoto, A.; Littman, D.R. Nuclear hormone receptors in T lymphocytes. Cell 2002, 109, S57–S66.

51. Kang, H.S.; Angers, M.; Beak, J.Y.; Wu, X.; Gimble, J.M.; Wada, T.; Xie, W.; Collins, J.B.; Grissom, S.F.; Jetten, A.M. Gene expression profiling reveals a regulatory role for ROR alpha and ROR gamma in phase I and phase II metabolism. Physiol. Genomics 2007, 31, 281–294.

52. Wang, Y.; Kumar, N.; Solt, L.A.; Richardson, T.I.; Helvering, L.M.; Crumbley, C.; Garcia-Ordonez, R.D.; Stayrook, K.R.; Zhang, X.; Novick, S.; Chalmers, M.J.; Griffin, P.R.; Burris, T.P. Modulation of retinoic acid receptor-related orphan receptor alpha and gamma activity by 7-oxygenated sterol ligands. J. Biol. Chem. 2010, 285, 5013–5025.
53. Wang, Y.; Kumar, N.; Crumley, C.; Griffin, P.R.; Burris, T.P. A second class of nuclear receptors for oxysterols: Regulation of RORalpha and RORgamma activity by 24S-hydroxycholesterol (cerebrosterol). *Biochim. Biophys. Acta* **2010**, *1801*, 917–923.

54. Wada, T.; Kang, H.S.; Jetten, A.M.; Xie, W. The emerging role of nuclear receptor RORalpha and its crosstalk with LXR in xeno- and endobiotic gene regulation. *Exp. Biol. Med.* **2008**, *233*, 1191–1201.

55. Jacob, L.; Lum, L. Deconstructing the hedgehog pathway in development and disease. *Science* **2007**, *318*, 66–68.

56. Varjosalo, M.; Taipale, J. Hedgehog signaling. *J. Cell. Sci.* **2007**, *120*, 3–6.

57. Corcoran, R.B.; Scott, M.P. Oxysterols stimulate Sonic hedgehog signal transduction and proliferation of medulloblastoma cells. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 8408–8413.

58. Dwyer, J.R.; Sever, N.; Carlson, M.; Nelson, S.F.; Beachy, P.A.; Parhami, F. Oxysterols are novel activators of the hedgehog signaling pathway in pluripotent mesenchymal cells. *J. Biol. Chem.* **2007**, *282*, 8959–8968.

59. Kim, W.K.; Meliton, V.; Amantea, C.M.; Hahn, T.J.; Parhami, F. 20(S)-hydroxycholesterol inhibits PPARgamma expression and adipogenic differentiation of bone marrow stromal cells through a hedgehog-dependent mechanism. *J. Bone Miner. Res.* **2007**, *22*, 1711–1719.

60. Johnson, J.S.; Meliton, V.; Kim, W.K.; Lee, K.B.; Wang, J.C.; Nguyen, K.; Yoo, D.; Jung, M.E.; Atti, E.; Tetradis, S.; Pereira, R.C.; Magyar, C.; Nargizyan, T.; Hahn, T.J.; Farouz, F.; Thies, S.; Parhami, F. Novel oxysterols have pro-osteogenic and anti-adipogenic effects in vitro and induce spinal fusion *in vivo*. *J. Cell. Biochem.* **2011**, *112*, 1673–1684.

61. Amantea, C.M.; Kim, W.K.; Meliton, V.; Tetradis, S.; Parhami, F. Oxysterol-induced osteogenic differentiation of marrow stromal cells is regulated by Dkk-1 inhibitable and PI3-kinase mediated signaling. *J. Cell. Biochem.* **2008**, *105*, 424–436.

62. Kim, W.K.; Meliton, V.; Tetradis, S.; Weinmaster, G.; Hahn, T.J.; Carlson, M.; Nelson, S.F.; Parhami, F. Osteogenic oxysterol, 20(S)-hydroxycholesterol, induces notch target gene expression in bone marrow stromal cells. *J. Bone Miner. Res.* **2010**, *25*, 782–795.

63. Nachtergaele, S.; Mydock, L.K.; Krishnan, K.; Rammohan, J.; Schlesinger, P.H.; Covey, D.F.; Rohatgi, R. Oxysterols are allosteric activators of the oncoprotein Smoothened. *Nat. Chem. Biol.* **2012**, *8*, 211–220.

64. Deroo, B.J.; Korach, K.S. Estrogen receptors and human disease. *J. Clin. Invest.* **2006**, *116*, 561–570.

65. Mendelsohn, M.E.; Karas, R.H. The protective effects of estrogen on the cardiovascular system. *N. Engl. J. Med.* **1999**, *340*, 1801–1811.

66. Murphy, E.; Steenbergen, C. Cardioprotection in females: A role for nitric oxide and altered gene expression. *Heart Fail. Rev.* **2007**, *12*, 293–300.

67. Umetani, M.; Domoto, H.; Gormley, A.K.; Yuhanna, I.S.; Cummins, C.L.; Javitt, N.B.; Korach, K.S.; Shaul, P.W.; Mangelsdorf, D.J. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. *Nat. Med.* **2007**, *13*, 1185–1192.

68. Dusell, C.D.; Umetani, M.; Shaul, P.W.; Mangelsdorf, D.J.; McDonnell, D.P. 27-hydroxycholesterol is an endogenous selective estrogen receptor modulator. *Mol. Endocrinol.* **2008**, *22*, 65–77.
69. DuSell, C.D.; Nelson, E.R.; Wang, X.; Abdo, J.; Modder, U.I.; Umetani, M.; Gesty-Palmer, D.; Javitt, N.B.; Khosla, S.; McDonnell, D.P. The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis. Endocrinology 2010, 151, 3675–8365.

70. Nelson, E.R.; Dusell, C.D.; Wang, X.; Howe, M.K.; Evans, G.; Michalek, R.D.; Umetani, M.; Rathmell, J.C.; Khosla, S.; Gesty-Palmer, D.; McDonnell, D.P. The oxysterol, 27-hydroxycholesterol, links cholesterol metabolism to bone homeostasis through its actions on the estrogen and liver x receptors. Endocrinology 2011, 152, 4691–4705.

71. Torres, C.G.; Ramirez, M.E.; Cruz, P.; Epunan, M.J.; Valladares, L.E.; Sierralta, W.D. 27-hydroxycholesterol induces the transition of MCF7 cells into a mesenchymal phenotype. Oncol. Rep. 2011, 26, 389–397.

72. Ikonen, E.; Vainio, S. Lipid microdomains and insulin resistance: Is there a connection? Sci. STKE 2005, 2005, doi:10.1126/stke.2682005pe3.

73. Patra, S.K. Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim. Biophys. Acta 2008, 1785, 182–206.

74. Olkkonen, V.M.; Hynynen, R. Interactions of oxysterols with membranes and proteins. Mol. Aspects Med. 2009, 30, 123–133.

75. Elmore, S. Apoptosis: A review of programmed cell death. Toxicol. Pathol. 2007, 35, 495–516.

76. Monier, S.; Samadi, M.; Prunet, C.; Denance, M.; Laubriet, A.; Athias, A.; Berthier, A.; Steinmetz, E.; Jurgens, G.; Negre-Salvayre, A.; Bessede, G.; Lemaire-Ewing, S.; Neel, D.; Gambert, P.; Lizard, G. Impairment of the cytotoxic and oxidative activities of 7 beta-hydroxycholesterol and 7-ketocholesterol by esterification with oleate. Biochem. Biophys. Res. Commun. 2003, 303, 814–824.

77. Biasi, F.; Leonarduzzi, G.; Vizio, B.; Zanetti, D.; Sevanian, A.; Sottero, B.; Verde, V.; Zingaro, B.; Chiarpotto, E.; Poli, G. Oxysterol mixtures prevent proapoptotic effects of 7-ketocholesterol in macrophages: Implications for proatherogenic gene modulation. FASEB J. 2004, 18, 693–695.

78. Leonarduzzi, G.; Biasi, F.; Chiarpotto, E.; Poli, G. Trojan horse-like behavior of a biologically representative mixture of oxysterols. Mol. Aspects Med. 2004, 25, 155–167.

79. Rutherford, L.D.; Gieseg, S.P. 7-ketocholesterol is not cytotoxic to U937 cells when incorporated into acetylated low density lipoprotein. Lipids 2011, (Epub ahead of print).

80. Lee, T.; Chau, L. Fas/Fas ligand-mediated death pathway is involved in oxLDL-induced apoptosis in vascular smooth muscle cells. Am. J. Physiol. Cell. Physiol. 2001, 280, C709–C718.

81. Lordan, S.; Mackrill, J.J.; O’Brien, N.M. Involvement of Fas signalling in 7beta-hydroxycholesterol- and cholesterol-5beta,6beta-epoxide-induced apoptosis. Int. J. Toxicol. 2008, 27, 279–285.

82. Lee, H.S.; Chang, J.S.; Baek, J.A.; Chung, M.Y.; Lee, H.C.; Rhim, B.Y.; Sok, D.E.; Rho, M.C.; Kim, Y.K.; Kim, K. TNF-alpha activates death pathway in human aorta smooth muscle cell in the presence of 7-ketocholesterol. Biochem. Biophys. Res. Commun. 2005, 333, 1093–1099.

83. Landis, M.S.; Patel, H.V.; Capone, J.P. Oxysterol activators of liver X receptor and 9-cis-retinoic acid promote sequential steps in the synthesis and secretion of tumor necrosis factor-alpha from human monocytes. J. Biol. Chem. 2002, 277, 4713–4721.
84. Prunet, C.; Montange, T.; Vejux, A.; Laubriet, A.; Rohmer, J.F.; Riedinger, J.M.; Athias, A.; Lemaire-Ewing, S.; Neel, D.; Petit, J.M.; Steinmetz, E.; Brenot, R.; Gambert, P.; Lizard, G. Multiplexed flow cytometric analyses of pro- and anti-inflammatory cytokines in the culture media of oxysterol-treated human monocytic cells and in the sera of atherosclerotic patients. Cytom. A 2006, 69, 359–373.

85. Erridge, C.; Webb, D.J.; Spickett, C.M. 25-Hydroxycholesterol, 7beta-hydroxycholesterol and 7-ketocholesterol upregulate interleukin-8 expression independently of Toll-like receptor 1, 2, 4 or 6 signalling in human macrophages. Free Radic. Res. 2007, 41, 260–266.

86. Lemaire, S.; Lizard, G.; Monier, S.; Miguel, C.; Gueldry, S.; Volot, F.; Gambert, P.; Neel, D. Different patterns of IL-1beta secretion, adhesion molecule expression and apoptosis induction in human endothelial cells treated with 7alpha-, 7beta-hydroxycholesterol, or 7-ketocholesterol. FEBS Lett. 1998, 440, 434–439.

87. Kim, R.; Emi, M.; Tanabe, K.; Murakami, S.; Uchida, Y.; Arihiro, K. Regulation and interplay of apoptotic and non-apoptotic cell death. J. Pathol. 2006, 208, 319–326.

88. Ryan, L.; O’Callaghan, Y.C.; O’Brien, N.M. Comparison of the apoptotic processes induced by the oxysterols 7beta-hydroxycholesterol and cholesterol-5beta,6beta-epoxide. Cell Biol. Toxicol. 2004, 20, 313–323.

89. Ghelli, A.; Porcelli, A.M.; Zanna, C.; Rugolo, M. 7-Ketocholesterol and staurosporine induce opposite changes in intracellular pH, associated with distinct types of cell death in ECV304 cells. Arch. Biochem. Biophys. 2002, 402, 208–217.

90. Kim, Y.J.; Lee, C.S. Tyrosine kinase inhibitor AG126 reduces 7-ketocholesterol-induced cell death by suppressing mitochondria-mediated apoptotic process. Neurochem. Res. 2010, 35, 603–612.

91. Gao, X.; Raghavamenon, A.C.; D’Auvergne, O.; Uppu, R.M. Cholesterol secoaldehyde induces apoptosis in J774 macrophages via mitochondrial pathway but not involving reactive oxygen species as mediators. Biochem. Biophys. Res. Commun. 2009, 389, 382–387.

92. Maddika, S.; Ande, S.R.; Panigrahi, S.; Paranjothy, T.; Weglarczyk, K.; Zuse, A.; Eshraghi, M.; Manda, K.D.; Wiechec, E.; Los, M. Cell survival, cell death and cell cycle pathways are interconnected: Implications for cancer therapy. Drug Resist. Updat. 2007, 10, 13–29.

93. Palozza, P.; Serini, S.; Verdechcia, S.; Ameruso, M.; Trombino, S.; Picci, N.; Monego, G.; Ranelletti, F.O. Redox regulation of 7-ketocholesterol-induced apoptosis by beta-carotene in human macrophages. Free Radic. Biol. Med. 2007, 42, 1579–1590.

94. Le Goff, D.; Viville, C.; Carreau, S. Apoptotic effects of 25-hydroxycholesterol in immature rat Sertoli cells: Prevention by 17beta-estradiol. Reprod. Toxicol. 2006, 21, 329–334.

95. Perales, S.; Alejandre, M.J.; Palomino-Morales, R.; Torres, C.; Iglesias, J.; Linares, A. Effect of oxysterol-induced apoptosis of vascular smooth muscle cells on experimental hypercholesterolemia. J. Biomed. Biotechnol. 2009, 2009, doi:10.1155/2009/456208.

96. Roussi, S.; Gosse, F.; Aoude-Werner, D.; Zhang, X.; Marchioni, E.; Geoffroy, P.; Miesch, M.; Raul, F. Mitochondrial perturbation, oxidative stress and lysosomal destabilization are involved in 7beta-hydroxysitosterol and 7beta-hydroxycholesterol triggered apoptosis in human colon cancer cells. Apoptosis 2007, 12, 87–96.
97. Lordan, S.; O’Brien, N.M.; Mackrill, J.J. The role of calcium in apoptosis induced by 7beta-hydroxycholesterol and cholesterol-5beta,6beta-epoxide. *J. Biochem. Mol. Toxicol.* **2009**, *23*, 324–332.

98. Anticoli, S.; Arciello, M.; Mancinetti, A.; de Martinis, M.; Ginaldi, L.; Iuliano, L.; Balsano, C. 7-ketocholesterol and 5,6-secosterol modulate differently the stress-activated mitogen-activated protein kinases (MAPKs) in liver cells. *J. Cell. Physiol.* **2010**, *222*, 586–595.

99. Jang, E.R.; Lee, C.S. 7-ketocholesterol induces apoptosis in differentiated PC12 cells via reactive oxygen species-dependent activation of NF-kappaB and Akt pathways. *Neurochem. Int.* **2011**, *58*, 52–59.

100. Liu, H.; Zhang, C.; Huang, K. Lanthanum chloride suppresses oxysterol-induced ECV-304 cell apoptosis via inhibition of intracellular Ca(2+) concentration elevation, oxidative stress, and activation of ERK and NF-kappaB signaling pathways. *J. Biol. Inorg. Chem.* **2011**, *16*, 671–681.

101. Laynes, L.; Raghavamenon, A.C.; D’Auvergne, O.; Achuthan, V.; Uppu, R.M. MAPK signaling in H9c2 cardiomyoblasts exposed to cholesterol secoaldehyde—Role of hydrogen peroxide. *Biochem. Biophys. Res. Commun.* **2011**, *404*, 90–95.

102. Lemaire-Ewing, S.; Berthier, A.; Royer, M.C.; Logette, E.; Corcos, L.; Bouchot, A.; Monier, S.; Prunet, C.; Ravenau, M.; Rebe, C.; Desrumaux, C.; Lizard, G.; Neel, D. 7beta-Hydroxycholesterol and 25-hydroxycholesterol-induced interleukin-8 secretion involves a calcium-dependent activation of c-fos via the ERK1/2 signaling pathway in THP-1 cells: Oxysterols-induced IL-8 secretion is calcium-dependent. *Cell Biol. Toxicol.* **2009**, *25*, 127–139.

103. Mascia, C.; Maina, M.; Chiarpotto, E.; Leonarduzzi, G.; Poli, G.; Biasi, F. Proinflammatory effect of cholesterol and its oxidation products on CaCo-2 human enterocyte-like cells: Effective protection by epigallocatechin-3-gallate. *Free Radic. Biol. Med.* **2010**, *49*, 2049–2057.

104. Dugas, B.; Charbonnier, S.; Baraine, M.; Ragot, K.; Delmas, D.; Menetrier, F.; Lherminier, J.; Malvitte, L.; Khalfaoui, T.; Bron, A.; Creuzot-Garcher, C.; Latruffe, N.; Lizard, G. Effects of oxysterols on cell viability, inflammatory cytokines, VEGF, and reactive oxygen species production on human retinal cells: Cytoprotective effects and prevention of VEGF secretion by resveratrol. *Eur. J. Nutr.* **2010**, *49*, 435–446.

105. Rodriguez, I.R.; Larrayoz, I.M. Cholesterol oxidation in the retina: Implications of 7KCh formation in chronic inflammation and age-related macular degeneration. *J. Lipid Res.* **2010**, *51*, 2847–2862.

106. Bauman, D.R.; Bitmansour, A.D.; McDonald, J.G.; Thompson, B.M.; Liang, G.; Russell, D.W. 25-Hydroxycholesterol secreted by macrophages in response to Toll-like receptor activation suppresses immunoglobulin A production. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 16764–16769.

107. Park, K.; Scott, A.L. Cholesterol 25-hydroxylase production by dendritic cells and macrophages is regulated by type I interferons. *J. Leukoc. Biol.* **2010**, *88*, 1081–1087.

108. Liu, C.; Yang, X.V.; Wu, J.; Kuei, C.; Mani, N.S.; Zhang, L.; Yu, J.; Sutton, S.W.; Qin, N.; Banie, H.; Karlsson, L.; Sun, S.; Lovenberg, T.W. Oxysterols direct B-cell migration through EBI2. *Nature* **2011**, *475*, 519–523.
109. Hannedouche, S.; Zhang, J.; Yi, T.; Shen, W.; Nguyen, D.; Pereira, J.P.; Guerini, D.; Baumgarten, B.U.; Roggo, S.; Wen, B.; Knochenmuss, R.; Noel, S.; Gessier, F.; Kelly, L.M.; Vanek, M.; Laurent, S.; Preuss, I.; Miault, C.; Christen, I.; Karuna, R.; Li, W.; Koo, D.I.; Suply, T.; Schmidt, C.; Peters, E.C.; Falchetti, R.; Katopodis, A.; Spanka, C.; Roy, M.O.; Detheux, M.; Chen, Y.A.; Schultz, P.G.; Cho, C.Y.; Seuwen, K.; Cyster, J.G.; Sailer, A.W. Oxysterols direct immune cell migration via EBI2. *Nature* **2011**, *475*, 524–527.

110. Castrillo, A.; Joseph, S.B.; Marathe, C.; Mangelsdorf, D.J.; Tontonoz, P. Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. *J. Biol. Chem.* **2003**, *278*, 10443–10449.

111. Ghisletti, S.; Huang, W.; Jepsen, K.; Benner, C.; Hardiman, G.; Rosenfeld, M.G.; Glass, C.K. Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways. *Genes Dev.* **2009**, *23*, 681–693.

112. Castrillo, A.; Joseph, S.B.; Vaidya, S.A.; Haberland, M.; Fogelman, A.M.; Cheng, G.; Tontonoz, P. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. *Mol. Cell Biol.* **2003**, *12*, 805–816.

113. Naiki, Y.; Sorrentino, R.; Wong, M.H.; Michelsen, K.S.; Shimada, K.; Chen, S.; Yilmaz, A.; Slepenkin, A.; Schroder, N.W.; Crother, T.R.; Bulut, Y.; Doherty, T.M.; Bradley, M.; Shaposhnik, Z.; Peterson, E.M.; Tontonoz, P.; Shah, P.K.; Arditi, M. TLR/MyD88 and liver X receptor alpha signaling pathways reciprocally control Chlamydia pneumoniae-induced acceleration of atherosclerosis. *J. Immunol.* **2008**, *181*, 7176–7185.

114. A-Gonzalez, N.; Bensinger, S.J.; Hong, C.; Beceiro, S.; Bradley, M.N.; Zelcer, N.; Deniz, J.; Ramirez, C.; Diaz, M.; Gallardo, G.; de Galarreta, C.R.; Salazar, J.; Lopez, F.; Edwards, P.; Parks, J.; Andujar, M.; Tontonoz, P.; Castrillo, A. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. *Immunity* **2009**, *31*, 245–258.

115. Bensinger, S.J.; Bradley, M.N.; Joseph, S.B.; Zelcer, N.; Janssen, E.M.; Hausner, M.A.; Shih, R.; Parks, J.S.; Edwards, P.A.; Jamieson, B.D.; Tontonoz, P. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. *Cell* **2008**, *134*, 97–111.

116. Sturley, S.L.; Patterson, M.C.; Balch, W.; Liscum, L. The pathophysiology and mechanisms of NP-C disease. *Biochim. Biophys. Acta* **2004**, *1685*, 83–87.

117. Wang, M.L.; Motamed, M.; Infante, R.E.; Abi-Mosleh, L.; Kwon, H.J.; Brown, M.S.; Goldstein, J.L. Identification of surface residues on Niemann-Pick C2 essential for hydrophobic handoff of cholesterol to NPC1 in lysosomes. *Cell. Metab.* **2010**, *12*, 166–173.

118. Du, X.; Kumar, J.; Ferguson, C.; Schulz, T.A.; Ong, Y.S.; Hong, W.; Prinz, W.A.; Parton, R.G.; Brown, A.J.; Yang, H. A role for oxysterol-binding protein-related protein 5 in endosomal cholesterol trafficking. *J. Cell Biol.* **2011**, *192*, 121–135.

119. Infante, R.E.; Abi-Mosleh, L.; Radhakrishnan, A.; Dale, J.D.; Brown, M.S.; Goldstein, J.L. Purified NPC1 protein. I. Binding of cholesterol and oxysterols to a 1278-amino acid membrane protein. *J. Biol. Chem.* **2008**, *283*, 1052–1063.
120. Infante, R.E.; Radhakrishnan, A.; Abi-Mosleh, L.; Kinch, L.N.; Wang, M.L.; Grishin, N.V.; Goldstein, J.L.; Brown, M.S. Purified NPC1 protein: II. Localization of sterol binding to a 240-amino acid soluble luminal loop. *J. Biol. Chem.* **2008**, *283*, 1064–1075.

121. Alpy, F.; Tomasetto, C. Give lipids a START: The StAR-related lipid transfer (START) domain in mammals. *J. Cell. Sci.* **2005**, *118*, 2791–2801.

122. Rodriguez-Agado, D.; Ren, S.; Hylemon, P.B.; Redford, K.; Natarajan, R.; Del Castillo, A.; Gil, G.; Pandak, W.M. Human StarD5, a cytosolic StAR-related lipid binding protein. *J. Lipid Res.* **2005**, *46*, 1615–1623.

123. Soccio, R.E.; Adams, R.M.; Maxwell, K.N.; Breslow, J.L. Differential gene regulation of StarD4 and StarD5 cholesterol transfer proteins. Activation of StarD4 by sterol regulatory element-binding protein-2 and StarD5 by endoplasmic reticulum stress. *J. Biol. Chem.* **2005**, *280*, 19410–19418.

124. Vihervaara, T.; Jansen, M.; Uronen, R.L.; Ohsaki, Y.; Ikonen, E.; Olkkonen, V.M. Cytoplasmic oxysterol-binding proteins: Sterol sensors or transporters? *Chem. Phys. Lipids* **2011**, *164*, 443–450.

125. Perry, R.J.; Ridgway, N.D. Oxysterol-binding protein and vesicle-associated membrane protein-associated protein are required for sterol-dependent activation of the ceramide transport protein. *Mol. Biol. Cell* **2006**, *17*, 2604–2616.

126. Banerji, S.; Ngo, M.; Lane, C.F.; Robinson, C.A.; Minogue, S.; Ridgway, N.D. Oxysterol binding protein-dependent activation of sphingomyelin synthesis in the golgi apparatus requires phosphatidylinositol 4-kinase Ialpha. *Mol. Biol. Cell* **2010**, *21*, 4141–4150.

127. Yan, D.; Lehto, M.; Rasilainen, L.; Metso, J.; Ehnholm, C.; Ylä-Herttuala, S.; Jauhiainen, M.; Olkkonen, V.M. Oxysterol binding protein induces upregulation of SREBP-1c and enhances hepatic lipogenesis. *Arterioscler. Thromb. Vasc. Biol.* **2007**, *27*, 1108–1114.

128. Botolin, D.; Wang, Y.; Christian, B.; Jump, D.B. Docosahexanoic acid (22:6,n-3) regulates rat hepatocyte SREBP-1 nuclear abundance by Erk- and 26S proteasome-dependent pathways. *J. Lipid Res.* **2006**, *47*, 181–192.

129. Bowden, K.; Ridgway, N.D. OSBP negatively regulates ABCA1 protein stability. *J. Biol. Chem.* **2008**, *283*, 18210–18217.

130. Wang, P.Y.; Weng, J.; Anderson, R.G. OSBP is a cholesterol-regulated scaffolding protein in control of ERK 1/2 activation. *Science* **2005**, *307*, 1472–1476.

131. Wang, P.Y.; Weng, J.; Lee, S.; Anderson, R.G. The N terminus controls sterol binding while the C terminus regulates the scaffolding function of OSBP. *J. Biol. Chem.* **2008**, *283*, 8034–8045.

132. Romeo, G.R.; Kazlauskas, A. Oxysterol and diabetes activate STAT3, and control endothelial expression of profilin-1 via OSBP1. *J Biol Chem* **2008**, *283*, 9595–9605.

133. Lessmann, E.; Ngo, M.; Leitges, M.; Minguet, S.; Ridgway, N.D.; Huber, M. Oxysterol-binding protein-related protein (ORP) 9 is a PDK-2 substrate and regulates Akt phosphorylation. *Cell Signal* **2007**, *19*, 384–392.

134. Zerbinatti, C.V.; Cordy, J.M.; Chen, C.D.; Guillily, M.; Suon, S.; Ray, W.J.; Seabrook, G.R.; Abraham, C.R.; Wolozin, B. Oxysterol-binding protein-1 (OSBP1) modulates processing and trafficking of the amyloid precursor protein. *Mol. Neurodegener* **2008**, *3*, doi:10.1186/1750-1326-3-5.
135. Ridgway, N.D.; Dawson, P.A.; Ho, Y.K.; Brown, M.S.; Goldstein, J.L. Translocation of oxysterol binding protein to Golgi apparatus triggered by ligand binding. *J. Cell Biol.* **1992**, *116*, 307–319.

136. Mohammadi, A.; Perry, R.J.; Storey, M.K.; Cook, H.W.; Byers, D.M.; Ridgway, N.D. Golgi localization and phosphorylation of oxysterol binding protein in Niemann-Pick C and U18666A-treated cells. *J. Lipid Res.* **2001**, *42*, 1062–1071.

137. Nhek, S.; Ngo, M.; Yang, X.; Ng, M.M.; Field, S.J.; Asara, J.M.; Ridgway, N.D.; Toker, A. Regulation of oxysterol-binding protein Golgi localization through protein kinase D-mediated phosphorylation. *Mol. Biol. Cell* **2010**, *21*, 2327–2337.

138. Amako, Y.; Sarkeshik, A.; Hotta, H.; Yates, J., 3rd; Siddiqui, A. Role of oxysterol binding protein in hepatitis C virus infection. *J. Virol.* **2009**, *83*, 9237–9246.

139. Amako, Y.; Syed, G.H.; Siddiqui, A. Protein kinase D negatively regulates hepatitis C virus secretion through phosphorylation of oxysterol-binding protein and ceramide transfer protein. *J. Biol. Chem.* **2011**, *286*, 11265–11274.

140. Auweter, S.D.; Yu, H.B.; Arena, E.T.; Guttman, J.A.; Finlay, B.B. Oxysterol-binding protein (OSBP) enhances replication of intracellular Salmonella and binds the Salmonella SPI-2 effector SseL via its N-terminus. *Microbes Infect.* **2011**, *14*, 148–154.

141. Yan, D.; Mäyränpää, M.I.; Wong, J.; Perttilä, J.; Lehto, M.; Jauhiainen, M.; Kovanen, P.T.; Ehnholm, C.; Brown, A.J.; Olkkonen, V.M. OSBP-related protein 8 (ORP8) suppresses ABCA1 expression and cholesterol efflux from macrophages. *J. Biol. Chem.* **2008**, *283*, 332–340.

142. Zhou, T.; Li, S.; Zhong, W.; Vihervaara, T.; Beaslas, O.; Perttilä, J.; Luo, W.; Jiang, Y.; Lehto, M.; Olkkonen, V.M.; Yan, D. OSBP-related protein 8 (ORP8) regulates plasma and liver tissue lipid levels and interacts with the nucleoporin Nup62. *PLoS One* **2011**, *6*, doi:10.1371/journal.pone.0021078.

143. Johansson, M.; Rocha, N.; Zwart, W.; Jordens, I.; Janssen, L.; Kuilj, C.; Olkkonen, V.M.; Neefjes, J. Activation of endosomal dynein motors by stepwise assembly of Rab7-RILP-p150Glued, ORP1L, and the receptor betalll spectrin. *J. Cell Biol.* **2007**, *176*, 459–471.

144. Vihervaara, T.; Uronen, R.L.; Wohlfahrt, G.; Björkhem, I.; Ikonen, E.; Olkkonen, V.M. Sterol binding by OSBP-related protein 1L regulates late endosome motility and function. *Cell. Mol. Life Sci.* **2011**, *68*, 537–551.

145. Rocha, N.; Kuilj, C.; van der Kant, R.; Janssen, L.; Houben, D.; Janssen, H.; Zwart, W.; Neefjes, J. Cholesterol sensor ORP1L contacts the ER protein VAP to control Rab7-RILP-p150 Glued and late endosome positioning. *J. Cell Biol.* **2009**, *185*, 1209–1225.

146. Levine, T.; Loewen, C. Inter-organelle membrane contact sites: Through a glass, darkly. *Curr. Opin. Cell Biol.* **2006**, *18*, 371–378.

147. Yan, D.; Jauhiainen, M.; Hildebrand, R.B.; van Dijk, K.W.; Van Berkel, T.J.C.; Ehnholm, C.; Van Eck, M.; Olkkonen, V.M. Expression of human OSBP-related protein 1L in macrophages enhances atherosclerotic lesion development in LDL receptor-deficient mice. *Arterioscler. Thromb. Vasc. Biol.* **2007**, *27*, 1618–1624.

148. Raychaudhuri, S.; Im, Y.J.; Hurley, J.H.; Prinz, W.A. Nonvesicular sterol movement from plasma membrane to ER requires oxysterol-binding protein-related proteins and phosphoinositides. *J. Cell Biol.* **2006**, *173*, 107–119.
149. Sullivan, D.P.; Ohvo-Rekila, H.; Baumann, N.A.; Beh, C.T.; Menon, A.K. Sterol trafficking between the endoplasmic reticulum and plasma membrane in yeast. *Biochem. Soc. Trans.* **2006**, *34*, 356–358.

150. Georgiev, A.G.; Sullivan, D.P.; Kersting, M.C.; Dittman, J.S.; Beh, C.T.; Menon, A.K. Osh proteins regulate membrane sterol organization but are not required for sterol movement between the ER and PM. *Traffic* **2011**, *12*, 1341–1355.

151. Ngo, M.; Ridgway, N.D. Oxysterol binding protein-related Protein 9 (ORP9) is a cholesterol transfer protein that regulates Golgi structure and function. *Mol. Biol. Cell* **2009**, *20*, 1388–1399.

152. Jansen, M.; Ohsaki, Y.; Rita Rega, L.; Bittman, R.; Olkkonen, V.M.; Ikonen, E. Role of ORPs in sterol transport from plasma membrane to ER and lipid droplets in mammalian cells. *Traffic* **2011**, *12*, 218–231.

153. Goldfinger, L.E.; Ptak, C.; Jeffery, E.D.; Shabanowitz, J.; Han, J.; Haling, J.R.; Sherman, N.E.; Fox, J.W.; Hunt, D.F.; Ginsberg, M.H. An experimentally derived database of candidate Ras-interacting proteins. *J. Proteome Res.* **2007**, *6*, 1806–1811.

154. Lehto, M.; Mäyränpää, M.I.; Pellinen, T.; P., I.; Lehtonen, S.; Kovanen, P.T.; Groop, P.H.; Ivaska, J.; Olkkonen, V.M. The R-Ras interaction partner ORP3 regulates cell adhesion. *J. Cell Sci.* **2008**, *121*, 695–705.

155. Fang, M.; Kearns, B.G.; Gedvilaite, A.; Kagiwada, S.; Kearns, M.; Fung, M.K.; Bankaitis, V.A. Kes1p shares homology with human oxysterol binding protein and participates in a novel regulatory pathway for yeast Golgi-derived transport vesicle biogenesis. *EMBO J.* **1996**, *15*, 6447–6459.

156. Li, X.; Rivas, M.P.; Fang, M.; Marchena, J.; Mehrotra, B.; Chaudhary, A.; Feng, L.; Prestwich, G.D.; Bankaitis, V.A. Analysis of oxysterol binding protein homologue Kes1p function in regulation of Sec14p-dependent protein transport from the yeast Golgi complex. *J. Cell Biol.* **2002**, *157*, 63–77.

157. Fairn, G.D.; Curwin, A.J.; Stefan, C.J.; McMaster, C.R. The oxysterol binding protein Kes1p regulates Golgi apparatus phosphatidylinositol-4-phosphate function. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 15352–15357.

158. Alfaro, G.; Johansen, J.; Dighe, S.A.; Duamel, G.; Kozminski, K.G.; Beh, C.T. The sterol-binding protein Kes1/Osh4p is a regulator of polarized exocytosis. *Traffic* **2011**, *12*, 1521–1536.

159. De Saint-Jean, M.; Delfosse, V.; Douguet, D.; Chicanne, G.; Payrastre, B.; Bourguet, W.; Antonny, B.; Drin, G. Osh4p exchanges sterols for phosphatidylinositol 4-phosphate between lipid bilayers. *J. Cell Biol.* **2011**, *195*, 965–978.

© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).